Description
Heat Biologics is a development-stage biopharmaceutical company engaged in the development of allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. Its ImmunePan Antigen Cytotoxic Therapy (ImPACT) is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to pump out a range of cancer-associated antigens together with a immune adjuvant called gp96 to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Its primary product candidates are HS-110 and HS-410. It is also developing ImPACT therapeutic vaccines for breast cancer and ovarian cancer.
Address
Suite 420, 100 Europa Drive
CHAPEL HILL, NC 27517
United States
CHAPEL HILL, NC 27517
United States
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | -3483.60% |
| Operating margin | - | 0.00% |
| EBITD margin | - | 83.28% |
| Return on average assets | -2.71% | -65.73% |
| Return on average equity | -1409.31% | - |
| Employees | 5 |
